About Us
Our mission and vision
LineaBio’s mission is to enable the cell and gene therapy industry by providing access to high-quality, off-the-shelf, GMP-compliant iPSC lines that streamline drug product manufacturing. By allowing therapeutic developers to cut costs and accelerate timelines to GMP, we strive to achieve our vision of making cell therapy universally accessible and affordable.
We operate using a flexible and transparent business model to be your trusted partner. LineaBio’s GMP-compliant iPSC lines are fully characterized, genetically stable, and supported by a drug master file.
Our history
Founded in 2023 by parent companies CCRM and OmniaBio, LineaBio draws on a team of iPSC experts that have been developing an iPSC platform since 2012. CCRM brings a track record of success in iPSC development, having completed the reprogramming of 200+ iPSC lines and the creation of 50+ gene-edited iPSC lines. As an affiliate of OmniaBio, a full-service, cell and gene therapy clinical and commercial contract development and manufacturing organization (CDMO), LineaBio’s customers can transition seamlessly to the manufacturing of a master cell bank and drug product. Together, we can offer developers an end-to-end solution for therapeutic development and manufacturing.
CCRM invests more than a decade into developing a leading reprogramming and gene editing platform.
LineaBio is founded by CCRM and OmniaBio to leverage expertise and build a series of off-the-shelf GMP iPSC lines.
